Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial

Post time 25 min. ago

Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
[size={"x":0,"y":110,"w":284,"h":21,"abs_x":22,"abs_y":894}]Anne Sophie V M van den Heerik, MD[url=]a[/url] Send email to [email protected][size={"x":284,"y":111,"w":13,"h":17,"abs_x":306,"abs_y":895}] ∙ [size={"x":297,"y":110,"w":194,"h":21,"abs_x":319,"abs_y":894}]Nanda Horeweg, MD PhD[url=]a[/url][size={"x":492,"y":111,"w":13,"h":17,"abs_x":514,"abs_y":895}] ∙ [size={"x":505,"y":110,"w":186,"h":21,"abs_x":527,"abs_y":894}]Marie A D Haverkort, MD[url=]b[/url][size={"x":692,"y":111,"w":13,"h":17,"abs_x":714,"abs_y":895}] ∙ [size={"x":705,"y":110,"w":193,"h":21,"abs_x":727,"abs_y":894}]Nienke Kuijsters, MD PhD[url=]c[/url][size={"x":899,"y":111,"w":13,"h":17,"abs_x":921,"abs_y":895}] ∙ [size={"x":913,"y":110,"w":199,"h":21,"abs_x":935,"abs_y":894}]Prof Stefan Kommoss, MD[url=]d[/url][size={"x":1112,"y":111,"w":8,"h":17,"abs_x":1134,"abs_y":895}] ∙ [size={"x":0,"y":131,"w":191,"h":21,"abs_x":22,"abs_y":915}]Friederike L A Koppe, MD[url=]e[/url][size={"x":191,"y":132,"w":48,"h":17,"abs_x":213,"abs_y":916}] ∙ et al.
[size={"x":0,"y":162,"w":0,"h":21,"abs_x":22,"abs_y":946}]

[size={"x":0,"y":186,"w":0,"h":21,"abs_x":22,"abs_y":970}]Publication History:
Published January 2026

DOI: 10.1016/S1470-2045(25)00612-6 External LinkAlso available on ScienceDirect External Link
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

[Elsevier] Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial